UPDATED: Upstart Ra sheds stealth status, targets new drug class

Cambridge, MA-based Ra Pharmaceuticals is stealth no more. Two years after it snagged an initial $10 million in venture cash, Ra has hauled in a second tranche of $8.6 million and picked its disease target: hereditary angioedema, a rare and lethal immune system disorder. And after maintaining strict silence as the biotech was being incubated at Morgenthaler Ventures, biotech vet Doug Treco today is going public, asserting that Ra is on the trail of a new drug class.

Ra's claim to fame will rest on Cyclomimetics, which Treco says will have the "diversity and specificity of antibodies, coupled with the beneficial properties of small molecules."

"The only FDA-approved treatment for the prevention of HAE attacks is delivered intravenously every 3 to 4 days and produced from human blood," Treco said in a statement. "Our synthetic Cyclomimetics are easily produced, and could offer a stable, highly potent option for patients suffering from HAE. In addition, Cyclomimetics have the potential to be orally-available, which would significantly increase the quality of life for patients with HAE." 

The inspiration for the biotech dates back 7 to 8 years, says Treco, when he was working in the lab of Nobel prize-winning scientist Jack Szostak, who's now chairman of Ra's scientific advisory group.

"We want to claim the middle ground between small molecules and proteins," Treco tells FierceBiotech this morning. "Proteins and monoclonals are outstanding drugs," he adds, characterized by low toxicity and capable of carrying out multiple functions. "But they can't get into cells, are expensive to manufacture and require injection." Small molecules, meanwhile, have great availability but lack specificity and often trigger off-target toxicity.

A new drug class involving a slightly larger molecule, though, could disrupt protein-protein interaction, offer great specificity and low toxicity. And Ra plans to create new peptides that can make it into cell membranes.

Treco says the biotech is on track to get into the clinic in about two years. And he's upbeat about the prospects of building "massive libraries" that can be used to develop a significant pipeline of therapies; some that it can keep, others that can be partnered. And he also expects to partner with drug developers who will come to Ra looking to solve some thorny problems. Ra has gathered together a staff of 19 and plans about seven more hires by the end of the year.

Treco is a familiar face in the rare disease space. He co-founded Transkaryotic, which Shire bought out in 2005 for $1.6 billion. Ra was initially incorporated in 2008 and gained a $27 million Series A commitment from New Enterprise Associates with Morgenthaler Ventures, Novartis Venture Funds and Amgen Ventures.

- here's the press release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.